Studies of APL patients (mostly adults) have shown that 20–30% of patients harbor in their leukemic cell the FLT3/internal tandem duplication (ITD) and another 10–20% carry the FLT3/tyrosine kinase domain (TKD) mutation. This evidence concerns the gene FLT3 and acute promyelocytic leukemia.